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Abstract: The HIV-1 ribonuclease H (RNase H) function of the reverse transcriptase (RT)
enzyme catalyzes the selective hydrolysis of the RNA strand of the RNA:DNA heteroduplex
replication intermediate, and represents a suitable target for drug development. A particularly
attractive approach is constituted by the interference with the RNase H metal-dependent
catalytic activity, which resides in the active site located at the C-terminus p66 subunit of
RT. Herein, we report results of an in-house screening campaign that allowed us to identify
4-[4-(aryl)-1H-1,2,3-triazol-1-yl]benzenesulfonamides, prepared by the “click chemistry” approach,
as novel potential HIV-1 RNase H inhibitors. Three compounds (9d, 10c, and 10d) demonstrated
a selective inhibitory activity against the HIV-1 RNase H enzyme at micromolar concentrations.
Drug-likeness, predicted by the calculation of a panel of physicochemical and ADME properties,
putative binding modes for the active compounds, assessed by computational molecular docking, as
well as a mechanistic hypothesis for this novel chemotype are reported.
Keywords: HIV-1 RNase H; click-chemistry; 4-[4-(aryl)-1H-1,2,3-triazol-1-yl]benzenesulfonamides;
docking
1. Introduction
Infections with Human Immunodeficiency Virus Type-1 (HIV-1), the causative agent of Acquired
Immunodeficiency Syndrome (AIDS), constitute a serious and global health problem [1–3]. Due to
the lack of an effective vaccine, antiretroviral treatment remains the only option for control, allowing
HIV-1 infection to transform from a highly lethal syndrome into a chronic condition. However, the
use and long-term effectiveness of these drugs have severe limitations, in particular the intrinsic
drug toxicity during long-term administration, the emergence of drug-resistant strains, poor patient
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compliance necessitating careful monitoring, and considerable costs. The current approach (also
termed High Active Anti-Retroviral Therapy, HAART) involves the combined inhibition of two or
three viral enzymes, protease (PR), integrase (IN), and especially reverse transcriptase (RT), which are
all essential for the virus to replicate.
Besides these validated pharmacological targets, the inhibition of the ribonuclease H (RNase H)
catalytic activity of the multifunctional RT enzyme has not yet been extensively explored as a suitable
antiviral strategy [4–8].
The HIV RT enzyme is associated with RNA- and DNA-dependent polymerase, RNase H strand
displacement, and strand transfer activities, which are required to transcribe the single-stranded vRNA
into double-stranded proviral vDNA.
From the structural point of view, RT is an asymmetrical heterodimer originating from two copies
of the p66 polypeptide that is encoded by the HIV pol gene. During viral maturation the C-terminal
portion of one p66 subunit is shortened by about 15 kDa, thus yielding the p51 polypeptide, which is
assembled with an uncut copy of p66 to form the mature enzyme. All the enzymatic activities reside
on the p66 subunit, whereas p51 lacks catalytic functions and only acts as a structural support. Subunit
p66 can be divided into five distinct domains; three of these are organized in a thumb-palm-fingers
fashion, and are the depository of the polymerase activities. A fourth connection domain separates the
hand from the RNase H domain located at the C-terminus of p66 (Figure 1).
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(N(t)RTIs) or non-nucleoside RT inhibitors (NNRTIs), and act by interfering with the polymerase 
activities of RT. However, despite the relatively high number of available compounds for 
combination therapy, drug effectiveness is hampered by the rapid emergence of drug-resistant 
viruses. One possible way to overcome this problem would be to inhibit the RNase H activity of RT. 
In fact, it is highly plausible that an additional RT inhibition mechanism could contribute 
synergistically to supress viral replication. 
From the functional point of view, HIV-1 RNase H, which catalyzes hydrolysis of the RNA part 
of the replicative intermediate DNA:RNA hybrid, is a member of the polynucleotidyl transferase 
superfamily. The tertiary structure of the HIV-1 RT RNase H active site is similar to that of all known 
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At present, more than 30 HIV blockers have been approved, with RT being the most successful
viral target. All marketed RT inhibitors belong to the classes of nucleoside/nucleotide RT inhibitors
(N(t)RTIs) or non-nucleoside RT inhibitors (NNRTIs), and act by interfering with the polymerase
activities of RT. However, despite the relatively high number of available compounds for combination
therapy, drug effectiveness is hampered by the rapid emergence of drug-resistant viruses. One possible
way to overcome this problem would be to inhibit the RNase H activity of RT. In fact, it is highly
plausible that an additional RT inhibition mechanism could contribute synergistically to supress
viral replication.
From the functional point of view, HIV-1 RNase H, which catalyzes hydrolysis of the RNA part
of the replicative intermediate DNA:RNA hybrid, is a member of the polynucleotidyl transferase
superfamily. The tertiary structure of the HIV-1 RT RNase H active site is similar to that of all
known RNases H, and contains five highly conserved residues that are essential for the catalysis:
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Asp443, Glu478, Asp498, Asp549 (the “DEDD motif”), and His539 [5,8,9]. Moreover, high resolution
crystallography of HIV-1 RT RNase H complexed to a RNA/DNA hybrid revealed that the DEDD
motif stabilizes two Mg2+ ions, which promotes cleavage of the phosphodiester bond of the RNA
chain, according to the “two-metal ions mechanism” [10,11].
As demonstrated for other polynucleotidyl transferases, HIV-1 RNase H can also be inhibited
through selective chelation of the metal cofactors [12]. During the last years, a few classes of compounds
capable of inhibiting HIV-1 RNase H activity by involving such a mechanism have been identified
(Figure 2), and include diketoacids/esters (1) [13–16], triketoacids (2) [17], β-thujaplicinol (3) [18],
2-hydroxyisoquinoline-1,3(2H,4H)-diones (HID, 4) [19], pymidinol carboxylic acids (5) [20],
naphthyridinones (5,6) [21,22], 3-hydroxy-2-oxo-1,2-dihydroquinoline-4-carboxamides (7) [23], and
4-(aryl)piperazin-1-yl)methyl)-7,8-dihydroxy-2H-chromen-2-ones (8) [24]. All these compounds share
a common pharmacophoric pattern constituted by at least three metal chelating features, which
usually consist of three oxygen atoms (compounds 1–5, and 8). In other examples, as outlined by
compounds 6 and 7, the minimal pharmacophore is formed by the combination of two oxygen atoms
and one nitrogen atom. However, neither of these compounds is currently moving into advanced
preclinical development.
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derivatives (9a–d and 10a–d, Figure 3), which we selected to also evaluate the influence of the 
perfluorination on the benzenesulfonamide chemotype. Moreover, we present a typical panel of 
physicochemical ADME parameters for the most active compounds, the interaction between a 
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In the course of a focused screening campaign using an in-house collection of molecules
specifically designed as metalloenzyme inhibitors, we found that compounds bearing the
4-(aryl–triazolyl)-benzenesulfonamide scaffold can act as novel HIV-1 RNase H inhibitors. Herein,
we report results on the HIV-1 RNase H, RT-associated DNA polymerase (DP) and HIV-1 integrase
(IN) inhibitory activities of two sets of 4-[4-(substituted)-1H-1,2,3-triazol-1-yl]benzenesulfonamide
derivatives (9a–d and 10a–d, Figure 3), which we selected to also evaluate the influence of the
perfluorination on the benzenesulfonamide chemotype. Moreover, we present a typical panel of
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physicochemical ADME parameters for the most active compounds, the interaction between a model
ligand and the Mg2+ ions, as well as computational docking studies to predict the possible binding
mode of our compounds within the enzyme active site.
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2. Results and Discussion
2.1. Compound Identification
The possibility that some metal-chelating inhibitors can block not only the specific target
for which they were designed, but also other metalloenzymes, has proven to be a consolidated
strategy for medicinal chemists [24]. In particular, this approach led us to identify novel classes of
influenza virus endonuclease inhibitors (i.e., salicyl thiosemicarbazones [25], and acyl hydrazones [26]),
as well as original prototypes (i.e., pyrazole-carboxylic acids) of carbonic anhydrase inhibitors
(CAIs) [27]. On this basis, we evaluated some representative compounds belonging to a general
class of 4-(4-substituted-triazole)-benzenesulfonamides, specifically designed as CAIs, as putative
HIV-1 RT-associated RNase H inhibitors.
To start, a library of selected metal-chelating compounds was preliminarily screened in order
to assess their ability to inhibit the HIV-1 RNase H activity. First, from an in-house library of about
250 compounds, we chose structural backbones carrying metal-coordinating functionalities. Next, after
a preliminary screening against the HIV-1 RNase H enzyme, a few hit compounds belonging to a novel
class of 4-(4-substituted-triazole)-benzenesulfonamides were identified. Among them, our attention
was drawn to derivatives 9a–d and 10a–d (Figure 3), which were submitted for further investigation.
Although the interaction between sulfonamides and Zn2+ ions is widely investigated and established,
coordination with Mg2+ appeared relatively novel; however, it is well known that deprotonated
oxygens are likely to establish an interaction with hard Lewis acid-like ions such as Mg(II). It is worth
nothing that the selected compounds 9a–d and 10a–d are representative of a collection previously
prepared by us using copper-catalyzed azide-alkyne cycloaddition (CuAAC) [28].
CuAAC is one of the most successful click chemistry methods because it allows us to create
large libraries of complex compounds with chemical diversity, starting from simple reactants [29,30].
Moreover, CuAAC reactions are usually high-yielding under facile and mild conditions, with the
possibility to generate and manage stereoselectivity.
In this scenario, compounds 9a–d and 10a–d were selected to preliminarily explore this chemical
space, in order to achieve a certain chemical diversity by modulating both the steric hindrance and
hydrophilic/lipophilic balance. Namely, the nature of the R moiety on the triazole was planned
considering various chemical functionalities including alkyl-(substituted)aromatic, hydroxyalkyl- or
aminoalkyl-substituents (Figure 3).
On the other hand, complete substitution of the hydrogens of an aromatic ring with fluorine
atoms is a well-known bioisosteric replacement strategy that, among other effects, dramatically
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increases the acidity of ring substituents without significantly affecting the steric properties of the
molecule [31]. In fact, the atomic size of fluorine is comparable to that of hydrogen, but its high
electronegativity produces several changes such as decrease of pKa, the modulation of lipophilicity
and other physicochemical parameters, which can lead to substantial variation of physicochemical
properties [31].
In order to study the influence of perfluorination on the activity of homologous
compounds, we re-synthesized two subclasses of derivatives (Scheme S1), where the first
bears a simple benzenesulfonamide scaffold (9a–d), while the second one carries a 2,3,5,6-
tetrafluorobenzenesulfonamide group (10a–d).
Moreover, we sought to predict the pKa of the sulfonamide group of these two sets of
compounds, under the presence or absence of perfluorination on the benzenesulfonamide ring.
From a computational prediction [32], the pKas were lowered approximately from six to 3.5, for
compounds 9a–d and 10a–d, respectively, and this should dramatically affect the ion speciation profile
of the tested compounds. In particular, at pH 7.4 the sulfonamide functionality of compounds 9a–d
would prevalently exist in non-deprotonated form, while at the same pH deprotonation of the
sulfamoyl group on fluorinated 10a–d should be favored. It was also supposed that the presence of a
negatively charged sulfonamide could increase the affinity of these compounds for the metal cofactors
of HIV-1 RNase H.
2.2. Interaction with Mg2+
Since RNase H active site inhibitors have been reported to chelate the Mg2+ ions [12–24], and to
support the hypothesis that the sulfonamide group could interact with the metal cofactors in the RNase
H catalytic pocket, we measured the capability of the model compound 10d to coordinate Mg2+ ions
by means of UV-visible (UV-vis) experiments. A series of UV-vis absorbance spectra of a methanolic
solution of 10d in the presence of increasing equivalents of Mg(CH3COO)2 were recorded (Figure 4).
We observed that increasing concentrations of Mg2+ produced a reduction of the maximum UV-vis
absorption, supporting the involvement of coordinative interactions between the sulfonamide and
metal ions.
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2.3. Biology
An enzymatic assay using recombinant HIV-1 RT and IN proteins was performed to assess the
ability to inhibit HIV-1 RT-associated RNase H and DP functions, and/or the IN catalytic process.
Within the series of 9a–d and 10a–d, three compounds (9d, 10c, and 10d) were endowed with selective
inhibitory activity towards RNase H (Table 1).
Table 1. HIV-1 RT-associated RNase H, RT-associated DNA polymerase, and HIV-1 IN inhibition
activities for 9a–d and 10a–d, and the previously described inhibitor RDS1759 [14], used as
reference compound.
Compound RNase H IC50 (µM) a DP IC50 (µM) b IN-LEDGF IC50 (µM) c
9a >100 ND ND
9b >100 ND ND
9c >100 ND ND
9d 63 ± 7 >100 >100
10a >100 ND ND
10b >100 ND ND
10c 26 ± 3 90 ± 5 >100
10d 6.6± 0.5 33.4± 5.8 >100
RDS1759 7.0 ± 1.5 ND ND
a Compound concentration required to inhibit the HIV-1 RNase H activity by 50%; b Compound concentration
required to inhibit the HIV-1 DP activity by 50%; c Compound concentration required to inhibit the HIV-1 IN
catalytic activity by 50% in the presence of LEDGF. ND, not determined. Inhibition activities of the most active
compound 10d are highlighted in bold.
With an IC50 value of 6.6 ± 0.5 µM, 10d was the most active compound of the series. Marginal or
moderate activities were registered for 9d (IC50 = 63 ± 7 µM) and 10c (IC50 = 26 ± 3 µM), respectively.
However, 10d and 10c also exhibited inhibition of the DP function (IC50 33.4 ± 5.8 and 90 ± 5 µM,
for 10d and 10c, respectively, Table 1), meaning that the potency for DP inhibition was much lower
compared to that for RNase H inhibition. In fact, their specificity indexes (SpI, expressed as the ratio
of the RNase H IC50 value vs. the DP IC50 value), were favorable to the RNase H function (SpI = ~5
and ~3.5, for 10d and 10c, respectively). Moreover, these compounds were inactive when tested for IN
inhibition (in the presence of the LEDGF cofactor and with 100 µM as the highest test concentration).
Overall, these data would support a relative selectivity toward RNase H enzymatic activity.
Although the number of tested compounds was not sufficient to perform a detailed
structure-activity relationships (SAR) analysis, these results allowed us to identify two key features that
seem important for activity: (a) the biaryl-triazole moiety, free or with an appropriate substituent (i.e.,
a n-pentyl tail); and (b) the perfluorination on the benzenesulfonamide ring. For example, since two of
the three active compounds possess both these features, we can hypothesize that the simultaneous
presence of the biaryl-triazole moiety and a small aliphatic chain in the position para may be a crucial
role for the activity. This can also be supported by the observation that small polar substituents (such
as OH or NH2) in position 4 of the triazole ring, as in compounds 9a,b, and 10a,b, dramatically abolish
the activity. These findings are consistent with those reported by Williams [21], Gerondelis [33], and
Vernekar [34], who suggested that the presence of an accessory biaryl motif, in addition to the aromatic
scaffold bearing the chelating group, is an important factor for HIV-1 RNase H inhibition.
As far as the perfluorination is concerned, the presence of tetrafluorine on the benzenesulfonamide
group led to an increase in potency, as observed by comparing the IC50 values of 9c and 10c (from
>100 µM to 26 µM), and 9d and 10d (from 63 µM to 6.6 µM), respectively.
Finally, the presence of the n-pentyl tail on the biaryltriazole shares an additional positive effect, as
observed by comparing the activity of compounds 9c and 9d (IC50 > 100 µM and 63 µM, respectively),
and of 10c and 10d (IC50 26 µM and 6.6 µM, respectively).
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2.4. Absorption, Distribution, Metabolism and Excretion Prediction
Determination of physicochemical properties and the related absorption, distribution, metabolism
and excretion (ADME) properties is a useful approach to predict the druggability and therapeutic
potential of a lead candidate [35]. Therefore, calculation of a panel of selective parameters important
to predict the solubility and membrane permeability for the most interesting compounds 9d, 10c,
and 10d was performed by considering Lipinski’s rule-of-five method (Table 2). According to this
procedure, a compound is likely to be well absorbed when it possesses a molecular weight <500,
number of H-bond acceptors <10, number of H-bond donors <5, and log P < 5 [36]. Moreover, other
parameters, such as the log S (−6.5 to 0.5) and the topological polar surface area (TPSA < 140 Å2),
that correlate with membrane permeability have been considered [37–39]. As shown in Table 2, the
calculated atom-based values (i.e., molecular weight, H-bond acceptor and donor counts, log P, log S
and TPSA) for 9d, 10c, and 10d meet desirable ADME criteria for good absorption and membrane
permeability, and are likely to yield favorable pharmacokinetic properties and bioavailability.
Table 2. Predicted physicochemical/ADME properties for compounds 9a–d, 10a–d, and RDS1759.
Compound MW H-acc H-don Rbond log P (o/w) log S TPSA
9d 370.5 4 1 7 3.328 −6.216 91
10c 372.3 2 1 3 1.829 −4.885 65
10d 442.4 2 1 7 3.928 −7.396 65
RDS1759 359.8 3 2 8 4.466 −4.103 69
Abbreviations: MW, molecular weight; H-acc, number of hydrogen bond acceptors; H-don, number of hydrogen
bond donors; Rbond, number of rotatable bonds; log P (o/w), log of the octanol-water partition coefficient ;
log S, log of the aqueous solubility; TPSA, topological polar surface area.
2.5. Docking
To predict the putative binding mode of the selected compounds 9d, 10c, and 10d, a series of
computational docking studies were performed. As displayed in Figure 5, docking results for the three
active compounds (9d, 10c, and 10d) revealed a tight affinity within the amino acid pocket located
near the catalytic site, which includes the following residues: Asp443-Arg448, Asn474, Glu478, Asp498,
Ala538-Lys540, and Asp549 (Figure 5, Figure S1). Although the common sulfonamide function of the
selected compounds is directed toward the metal ions, the orientation of their aromatic backbones
appears different within two pockets, probably depending on the presence (9d and 10d) or absence (10c)
of the aliphatic n-pentyl tail. In particular, the most favorable conformation of 9d and 10d is placed
along the surface of the protein, with the 4-pentylphenyltriazole accommodated in a cavity surrounding
the active site formed by residues Asn265, Trp266, Ser268, Gln269, Ile274, and Lys275 (Figure 5A,C
for 9d and 10d, respectively). Strong arene-cation interactions between the 4-pentylbenzene ring and
Lys540, for both 9d and 10d, were revealed. Otherwise, compound 10c (Figure 5B) is engaged into
a second pocket, with the benzene ring placed in a narrow cavity lined by residues Ala446-Glu449,
Ile556, and Arg557, in close proximity to the catalytic site. Similarly to 9d and 10d, the distal benzene
ring of 10c is also involved in an arene-cation interaction, in this case with Arg448, which establishes a
second arene-cation interaction with the triazole ring.
Significant differences could be rationalized on the coordination of metal cofactors by each
compound. In particular, in 9d (dG = 11.9648 kcal·mol−1, IC50 = 63 µM), which bears a neutral
sulfonamide group, one oxygen of the sulfonamide group is bridging between the two metal cofactors
(Mn2+ ions are present in the 3LP2 X-ray structure, Figure S1A). Comparatively, each oxygen of the
sulfonamide group of 10c (dG = 14.2330 kcal·mol−1, IC50 = 26 µM) appeared involved in one bond
(two bonds in total) with one metal ion (Figure S1B): in this way, the ligand produced µ2-bridging
between the two metal ions. Interestingly, the most active derivative 10d (dG = 19.4250 kcal·mol−1,
IC50 = 6.6 µM) is predicted to coordinate one manganese cation with both sulfonamide oxygens; one
of the two chelating oxygens shows an additional interaction with the second cation (Figure S1C).
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These interactions would presumably concur, together with the molecules of the solvent and with
amino acids on the catalytic pocket, to complete the coordination geometry around the metal, favoring
chelation of metal cofactors and, consequently, the inhibitory activity.
These results suggest that the activity of these compounds can be explained by their arrangement
in the active site of the enzyme. The superior potency of 10d (IC50 = 6.6 ± 0.5 µM) can be attributed to
the optimal pKa of the sulfonamide group, as well as to a favorable orientation of the chelating motif,
which should significantly contribute to its metal coordination.
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Figure 5. Predicted binding modes for the most active compounds 9d, 10c, and 10d within the HIV-1
RNase H catalytic site: (A–C) best docking pose for 9d (purple), 10c (cyan), and 10d (white), respectively,
with the protein shown as grey surface, and with the contact residues colored in the same color as the
docked ligand; (D–F) close views of the binding site, where the protein is depicted as cartoon (blue
lagoon), side chains of relevant residues are provided as thick line (pink), and Mn2+ metal cofactors as
spheres (orange).
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3. Materials and Methods
3.1. Chemistry
Compounds 9a–d and 10a–d, were prepared following a synthetic procedure previously reported
by us [28]. The experimental details and characterization data are detailed in the Supporting
Information. Briefly, the title compounds 9a–d and 10a–d were synthesized by reacting the azides 11
and 12 with alkynes 13b–d,e in the presence of nanosized metallic copper as catalyst (Scheme S1) [28].
3.2. UV-Visible Titration
UV-vis absorption spectra of 10d were registered by a spectrophotometer uniSPEC 2 (LLG
Labware, BDL Czech Republic sro, Turnov, Czech Republic) using a 0.025 mM solution in methanol.
Each metal/ligand (M:L) system was studied by titrating a 3.0 mL of the ligand solution with
a methanolic solution of Mg(CH3COO)2 (5 mM); spectra of samples with M:L molar ratio ranging
from 0 to 10 were measured.
3.3. Biology
3.3.1. Protein Expression and Purification
The recombinant HIV-1 RT protein, the coding gene of which was subcloned in the p6HRT_prot
plasmid, was expressed in E. coli strain M15 [40,41]. The bacteria cells were grown up to an optical
density (at 600 nm) of 0.8 and induced with 1.7 mM isopropyl β-D-1-thio galactopyranoside (IPTG) for
5 h. HIV-1 RT purification was performed as described [42]. Briefly, cell pellets were re-suspended
in lysis buffer (20 mM HEPES, pH 7.5; 0.5 M NaCl; 5 mM β-mercaptoethanol; 5 mM imidazole;
0.4 mg·mL−1 lysozyme), incubated on ice for 20 min, sonicated, and centrifuged at 30,000× g for
1 h. The supernatant was applied to a His-binding resin column and washed thoroughly with wash
buffer (20 mM HEPES, pH 7.5; 0.3 M NaCl; 5 mM β-mercaptoethanol; 60 mM imidazole; 10% glycerol).
RT was eluted by imidazole gradient, and the enzyme-containing fractions were pooled and dialyzed
and aliquots were stored at −80 ◦C.
3.3.2. HIV-1 RNase H Polymerase-Independent Cleavage Assay
The HIV-1 RT-associated RNase H activity was measured as described [42] in 100 µL reaction
volume containing 50 mM Tris HCl, pH 7.8; 6 mM MgCl2, 1 mM dithiothreitol (DTT), 80 mM KCl,
0.25 µM hybrid RNA/DNA (5′-GTT TTC TTT TCC CCC CTG AC-3′-fluorescein, 5′-CAA AAG AAA
AGG GGG GAC UG-3′-dabcyl) and 3.8 nM RT. The reaction mixture was incubated for 1 h at 37 ◦C.
The enzymatic reaction was stopped with the addition of ethylenediaminetetraacetic acid (EDTA) and
measured with a Victor3 instrument (Perkin) at 490/528 nm.
3.3.3. HIV-1 RT-Associated RNA-Dependent DNA Polymerase Activity Determination
The HIV-1 RT-associated RNA-dependent DP activity was measured as previously described [23].
Briefly, 20 ng of HIV-1 wt RT was incubated for 30 min at 37 ◦C in 25 mL volume containing 60 mM
Tris HCl, pH 8.1, 8 mM MgCl2, 60 mM KCl, 13 mM DTT, 2.5 mM poly(A)-oligo(dT), 100 mM
dTTP. Enzymatic reaction was stopped by addition of EDTA. Reaction products were detected by
picogreen addition and measured with a PerkinElmer Victor 3 multilabel counter plate reader at
excitation-emission wavelength of 502/523 nm. Chemical reagents were purchased form Sigma Aldrich
srl. RNA-DNA labelled sequences were purchased from Metabion international AG.
3.3.4. HIV-1 IN/LEDGF HTRF LEDGF-Dependent Assay
Recombinant IN and LEDGF/p75 were purified as described by Esposito et al. [43].
The INLEDGF/p75-dependent assay allow to measure the inhibition of 3′-processing and strand
transfer IN reactions in presence of recombinant LEDGF/p75 protein, as previously described [44].
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Briefly, 50 nM IN was pre-incubated with increasing concentration of compounds for 1 h at room
temperature in reaction buffer containing 20 mM HEPES pH 7.5, 1 mM DTT, 1% Glycerol, 20 mM
MgCl2, 0.05% Brij-35 and 0.1 mg/mL BSA. DNA donor substrate, DNA acceptor substrate and 50 nM
LEDGF/p75 protein were added and incubated at 37 ◦C for 90 min. After the incubation, 4 nM of
Europium-Streptavidine were added at the reaction mixture and the HTRF signal was recorded using
a Perkin Elmer Victor 3 plate reader using a 314 nm for excitation wavelength and 668 and 620 nm for
the wavelength of the acceptor and the donor substrates emission, respectively.
3.4. Molecular Modeling
3.4.1. Hardware Specifications
All calculations were performed on a 64 bit Intel 8-Core i7-2600 CPU (Hewlett Packard, Palo Alto,
CA, USA) running at 3.40 GHz with 8 GB RAM.
3.4.2. Protein Preparation
The coordinates of full-length mutant HIV-1 RT were retrieved from RCSB Protein Data Bank
(accession code 3LP2). Wild-type enzyme was obtained by retro-mutation of Asp103 to Lysine, then
the missed residue Arg557 belongings to the HIV-1 RNase H active site was modeled using the crystal
complex 3K2P, as previously described [14]. The protein was prepared using Molecular Operating
Environment software package platform (MOE, version 2009.10, Chemical Computing Group Inc.,
Montreal, QC, Canada) [45] as follows: solvent molecules were removed, and chains termini were
capped; then all hydrogens were added to the system, partial atomic charges were assigned according
OPLS_AA force field, and minimization procedure was applied in order to optimize atoms positions.
3.4.3. Ligands Preparation
The ligands were built using MOE builder mask. For each ligand the predicted most representative
species at pH 7.4 was considered. Thus, compounds 9c was modeled as neutral species, whereas
for compounds 10c and 10d, due to the tetrafluorination, the mono-deprotonated sulfonamide form
was considered. The geometries of the ligands were optimized by an energy minimization pass until
a convergence gradient of 0.01 kJ (mol·Å)−1 was reached using the MMFF94x force field. Solvent effect
was calculated using the Generalized Born Solvation Model.
3.4.4. Docking Procedures
Triangle Matcher Placement docking method implemented in MOE platform was used to re-dock
the co-crystallized ligand of 3LP1 on the HIV-1 RNase H active site. The results were scored using
London dG as rescoring, Forcefield as refinement, and Affinity dG as second rescoring functions.
The same protocol was applied to the database containing our ligands.
4. Conclusions
In summary, we identified original 4-[4-(substituted)-1H-1,2,3-triazol-1-yl]benzenesulfonamides
as potential inhibitors of the HIV-1 RNase H function. This study highlighted that key features
such as a (substituted) biaryl moiety and perfluorination on the benzenesulfonamide ring are crucial
for the inhibitory activity of this class of compounds. These insights resulted in compound 10d as
a representative and interesting lead compound for drug optimization. Moreover, spectroscopic
analyses and molecular modeling studies indicated that such derivatives can mechanistically act by
interfering with the two-metal ions through direct coordination of the metal cofactors in the enzyme
catalytic site. This is in agreement with the behavior of diketo/triketoacid derivatives [14], but
differs from what was observed for allosteric inhibitors [6,18] and dual inhibitors of RNase H and
RT-associated DP activity, which were recently proposed to bind to a site close, but not coincident, to
the RNase H active site [46]. Finally, calculated ADME properties and the preliminary finding that 10d
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displayed cellular cytotoxicity in human MT-4 cells at >7 µM, which was evaluated within the range
of its inhibition concentration, predict that this compound can have desirable drug-like properties,
thus making it suitable for further development.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/8/1371/s1.
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